OC
TEVA icon

Oppenheimer & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Oppenheimer & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Buy
9,574
+2,930
+44% +$97.6K ﹤0.01% 1443
2026
Q1 		$200K Sell
6,644
-1,666
-20% -$53.6K ﹤0.01% 1577
2025
Q4 		$259K Sell
8,310
-3,189
-28% -$78.6K ﹤0.01% 1327
2025
Q3 		$232K Buy
11,499
+1,389
+14% +$24.4K ﹤0.01% 1490
2025
Q2 		$169K Buy
+10,110
New +$163K ﹤0.01% 1523
2025
Q1 		– Sell
-10,278
Closed -$227K – 1662
2024
Q4 		$227K Sell
10,278
-22,124
-68% -$402K ﹤0.01% 1405
2024
Q3 		$584K Buy
32,402
+13,215
+69% +$231K 0.01% 985
2024
Q2 		$312K Buy
19,187
+5,665
+42% +$87.3K ﹤0.01% 1176
2024
Q1 		$191K Buy
13,522
+1,180
+10% +$14.9K ﹤0.01% 1350
2023
Q4 		$129K Sell
12,342
-1,073
-8% -$10K ﹤0.01% 1323
2023
Q3 		$137K Sell
13,415
-4,455
-25% -$41.5K ﹤0.01% 1302
2023
Q2 		$135K Sell
17,870
-45,163
-72% -$366K ﹤0.01% 1332
2023
Q1 		$558K Sell
63,033
-7,513
-11% -$74.3K 0.01% 899
2022
Q4 		$643K Sell
70,546
-6,707
-9% -$58.5K 0.01% 837
2022
Q3 		$623K Buy
77,253
+3,500
+5% +$30.9K 0.01% 815
2022
Q2 		$554K Sell
73,753
-18,075
-20% -$157K 0.01% 882
2022
Q1 		$861K Buy
91,828
+44,343
+93% +$370K 0.02% 797
2021
Q4 		$381K Sell
47,485
-4,910
-9% -$44.3K 0.01% 1128
2021
Q3 		$511K Sell
52,395
-8,890
-15% -$83.2K 0.01% 1012
2021
Q2 		$606K Sell
61,285
-9,236
-13% -$97.8K 0.01% 940
2021
Q1 		$814K Sell
70,521
-5,472
-7% -$62.7K 0.02% 776
2020
Q4 		$734K Sell
75,993
-27,769
-27% -$266K 0.02% 749
2020
Q3 		$935K Buy
103,762
+2,203
+2% +$23.3K 0.02% 613
2020
Q2 		$1.25M Sell
101,559
-56,978
-36% -$644K 0.03% 497
2020
Q1 		$1.43M Buy
158,537
+63,139
+66% +$647K 0.04% 425
2019
Q4 		$935K Sell
95,398
-4,512
-5% -$40.3K 0.02% 642
2019
Q3 		$687K Sell
99,910
-13,571
-12% -$104K 0.02% 694
2019
Q2 		$1.05M Sell
113,481
-4,275
-4% -$51.5K 0.03% 582
2019
Q1 		$1.85M Sell
117,756
-8,883
-7% -$157K 0.05% 409
2018
Q4 		$1.95M Sell
126,639
-1,639
-1% -$33.6K 0.06% 344
2018
Q3 		$2.76M Buy
128,278
+11,947
+10% +$277K 0.07% 308
2018
Q2 		$2.83M Buy
116,331
+11,428
+11% +$233K 0.08% 302
2018
Q1 		$1.79M Sell
104,903
-18,524
-15% -$362K 0.05% 426
2017
Q4 		$2.34M Sell
123,427
-27,242
-18% -$410K 0.06% 344
2017
Q3 		$2.65M Buy
150,669
+5,365
+4% +$121K 0.07% 312
2017
Q2 		$4.83M Sell
145,304
-5,147
-3% -$159K 0.13% 183
2017
Q1 		$4.83M Sell
150,451
-28,760
-16% -$981K 0.14% 173
2016
Q4 		$6.5M Buy
179,211
+114,902
+179% +$4.59M 0.19% 127
2016
Q3 		$2.96M Sell
64,309
-50,312
-44% -$2.62M 0.09% 270
2016
Q2 		$5.76M Buy
114,621
+27,774
+32% +$1.48M 0.17% 127
2016
Q1 		$4.65M Sell
86,847
-4,786
-5% -$281K 0.14% 167
2015
Q4 		$6.01M Sell
91,633
-26,459
-22% -$1.64M 0.18% 127
2015
Q3 		$6.67M Buy
118,092
+6,182
+6% +$401K 0.2% 113
2015
Q2 		$6.61M Sell
111,910
-4,524
-4% -$279K 0.18% 127
2015
Q1 		$7.25M Buy
116,434
+2,270
+2% +$132K 0.2% 118
2014
Q4 		$6.57M Sell
114,164
-32,561
-22% -$1.81M 0.19% 128
2014
Q3 		$7.89M Sell
146,725
-6,096
-4% -$323K 0.23% 105
2014
Q2 		$8.01M Buy
152,821
+2,289
+2% +$117K 0.24% 101
2014
Q1 		$7.96M Buy
150,532
+11,068
+8% +$512K 0.24% 98
2013
Q4 		$5.59M Buy
139,464
+13,735
+11% +$541K 0.18% 141
2013
Q3 		$4.75M Buy
125,729
+2,941
+2% +$115K 0.17% 157
2013
Q2 		$4.81M Buy
+122,788
New +$4.78M 0.19% 141

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Oppenheimer & Co's TEVA Position: Q2 2026 in Review

Oppenheimer & Co increased its Teva Pharmaceuticals (TEVA) stake by 44% in Q2 2026, buying an estimated $97.6K and bringing the position to 9,574 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

Oppenheimer & Co first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.01M in Q2 2014. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Oppenheimer & Co held 9,574 shares of Teva Pharmaceuticals worth $324K as of Q2 2026.
  • Oppenheimer & Co bought 2,930 Teva Pharmaceuticals shares in Q2 2026, an estimated $97.6K.
  • Teva Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1443 holding.
  • Oppenheimer & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Teva Pharmaceuticals position peaked at $8.01M in Q2 2014.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.